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Abstract
Today, bronchial asthma is the most widespread childhood chronic respiratory disease in the world. To make managerial 
decisions in the health care system of Ukraine and to identify priority areas for the response to this disease, it is necessary to carry 
out a quantitative analysis of the appointment letters and the proportion of patients who received specific drugs for determining the 
main areas of therapy.
Aim. Carrying out of frequency analysis of medical prescriptions at pharmacotherapy of bronchial asthma in children. 
Materials and methods. 574 medical cards of an indoor patient with the main diagnosis of “Bronchial asthma”, received at 
the Kyiv City Children’s Clinical Hospital No. 2. A retrospective frequency analysis of the prescribing of drugs for archival data of 
appointment letters was conducted. 
Results. The conducted analysis of patients by age and sex allowed to establish the correspondence of the obtained results 
with the results of previous scientific studies on gender differences in the prevalence of bronchial asthma in children. In 45.3 % of the 
children, the length of stay was 2–10 days, and in 37.3 % – 11–20 days, indicating a sufficiently long period of inpatient treatment. 
According to the letters of appointment in the medical records of the inpatient patient, the physicians carried out 1983 appointments, 
of which 1867 were medicated (94.2 %), and 116 were non-medicated methods (5.8 %). The medical appointments of doctors in-
cluded 1763 medicines. Of these, 94.4 % are medicines belonging to 11 groups according to ATC classification, 1.5 % – solutions 
for washing, irrigation, treatment, 0.3 % – dietary supplements, 0.1 % – homeopathic preparations, 3.7 % – other. The data that was 
obtained when calculating the intensity of the target varies in the range of 0.0006 to 0.07. The highest rates had only 2 drugs – Ven-
tolin nebuli and Pulmicort, which were available in 22.3 % and 23.0 % of the patient’s medical cards respectively, that is, every fifth 
patient. It was found that the ratio of drugs of domestic and foreign manufacture is 34.2 % (20 pharmaceutical companies) and 65.8 % 
(25 producing countries), respectively.
Conclusions. The received data of the conducted analysis of prescriptions of medicinal products allow establishing a signifi-
cant nomenclature of medical appointments for children with bronchial asthma. The promising direction for domestic pharmaceuti-
cal companies in the production of drugs for the treatment of the examined nosology was revealed. At the same time, the frequency 
analysis of the nomenclature of drugs can be used in the selection of drugs for reimbursement programs and medical insurance after 
further pharmacoeconomic studies.
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1. Introduction
Today, bronchial asthma (BA) is the most widespread childhood chronic respiratory dis-
ease in the world. According to the prevalence, severity and insufficient diagnostic criteria, the 
disease is a “disease of the century”, since it requires significant expenses for pharmacotherapy, 
emergency and inpatient care, rehabilitation, and also reduces the quality of life of children and 
their families [1, 2].
The average annual cost of asthma treatment is quite high and for one child it is € 929.35, 
of which € 698.65 is a direct expense and € 230.70 indirect. However, in children with partially 
controlled or uncontrolled BA, the average cost per year is significantly higher. The study of 
the very economic aspects of BA pharmacotherapy is relevant for the adoption of management 
decisions in the health care system of Ukraine and in determining priority areas for the response 
to this disease [3, 4].
The urgency of this issue is indicated in a number of normative legal documents. Thus, the 
main areas of development of the pharmaceutical industry are to increase the level of population 
provision with effective, safe and high-quality drugs for affordable pharmacotherapy, which is 
specified in the Law of Ukraine “Fundamentals of the legislation of Ukraine on health” and in 
the Concept of development of the pharmaceutical sector of the health care sector of Ukraine for 
2011–2020 [5, 6].
In connection with the foregoing for this nosology, it is necessary to carry out a quanti-
tative analysis of the appointment letters and the proportion of patients who received specific 
drugs to determine the main areas of therapy. There is also a need to identify leaders among 
drugs which are preferred by doctors, since the quality of diagnosis and treatment of asthma still 
needs to be improved.
In a number of analyzed publications in recent years, the issues of clinical and economic 
analysis of the pharmaceutical supply of various diseases, such as gynecological diseases [7], isch-
emic heart disease [8], lumbar ischialgia [9], metabolic syndrome [10], tonsillitis [11], chronic cho-
lecystitis [12]. Special attention was devoted to such researches of children’s diseases, namely viral 
diarrhea [13], acute nasopharyngitis [14], pertussis, scarlet fever, meningococcal infection [15], 
outpatient pneumonia [16], functional dyspepsia [17], but medical research of the appointments of 
asthma pharmacotherapy in children have not been performed before. 
2. Aim of the research
Carry out a frequency analysis of medicinal prescriptions for pharmacotherapy of asthma in 
children to increase the availability of pharmaceutical assistance to a certain category of patients. 
3. Materials and methods
The materials of the study were 574 medical cards of the indoor patient with the main di-
agnosis of “Bronchial asthma”. Patients were treated at the Kyiv City Children’s Clinical Hospital 
No. 2 (duration of the study is January-December 2018). The information collection was performed 
according to the following key parameters: date, diagnosis, patient (gender and age), medical ap-
pointment (trade name, international non-proprietary name, ATC code, dosage form, duration of 
treatment, number of appointments).
Methods of research: retrospective frequency analysis of the appointments of medicines for 
archival data of medical cards of inpatient patients, statistical, analytical, and graphic.
4. Results
As a result of the analysis of patients by age and sex, it was found that among the total num-
ber of patients, 439 were boys (76.5 %) and 135 were girls (23.5 %), which corresponds to research 
data of scholars about sex differences in the prevalence of asthma in children [18–20]. The average 
age for boys is 11.6 years, and for girls – 10.3. However, the largest number of sick boys was aged 
15–16 years, and among girls – 6–8 years. People of early age (up to 5 years old) had low rates of 
morbidity, which can be explained by the lack of early diagnosis and the diagnosis of “Bronchial 
asthma” (Fig. 1).
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Fig. 1. Sample distribution by gender and age
Also, we analyzed the length of stay of patients in the hospital. Thus, the number of bed days 
varied from 2 to 51 (the average – 14.2 per 1 patient). In 45.3 %, the length of stay was 2–10 days, 
and in 37.3 % – 11–20 days (Table 1). These figures suggest a sufficiently long period of inpatient 
treatment that affects the overall cost of the disease. 
Table 1
Results of the combined analysis of the length of stay of patients on indoor treatment
Number of bed days Number of patients %
2–10 260 45.3
11–20 214 37.3
21–30 40 7.0
More than 30 60 10.4
In order to evaluate the frequency of use of drugs in the pharmacotherapy of asthma in 
children, we conducted a frequency analysis of pharmacotherapeutic groups and trade names. Ac-
cording to the letters of appointment in the medical records of the inpatient patient, the physicians 
carried out 1983 appointments, of which 1867 were medicated (94.2 %) and 116 were non-medicat-
ed methods (5.8 %).
The medical appointments of doctors included 1763 drugs. Of these, 94.4 % are drugs be-
longing to 11 groups according to ATC classification, 1.5 % – solutions for washing, irrigation, 
treatment, 0.3 % – dietary supplements, 0.1 % – homeopathic preparations, 3.7 % – other (Table 2). 
Table 2
Frequency analysis of medical prescriptions for the treatment of children with bases of the ATC classification
АТС-code Nomenclature Frequency of  prescriptions
 % from the total number 
of prescriptions
A Alimentary tract and metabolism 21 1.2
В Blood and blood forming organs 5 0.3
С Cardiovascular system 3 0.2
D Dermatologicals 20 1.1
Н
Systemic hormonal preparations, excluding sex hormones 
and insulins 5 0.3
J Antiinfectives for systemic use 85 4.8
М Musculo-skeletal system 3 0.2
N Nervous system 9 0.5
Р Antiparasitic products, insecticides and repellents 2 0.1
R Respiratory system 1558 88.4
S Sensory organs 52 2.9
Total 1763 100
0
10
20
30
40
50
60
70
80
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17
0
3 4 9
14
31
18
38
23 21
36 29 30 36
64
56
27
0 1
5
4
13
9
17
15 12
14
8 6
8
7
8
8
Boys Girls
Original Research Article:
full paper
(2019), «EUREKA: Health Sciences»
Number 3
47
Pharmacology, Toxicology and Pharmaceutical Science
According to the data in Table 2, the group R – “Respiratory system” (86.7 %) is in the 
lead, which needs a more detailed analysis (Tab. 3). It is estimated that the largest number of ap-
pointments have subgroups: R01A “Decongestants and other nasal preparations for topical use” 
(25.2 %), R03A “Adrenergics, inhalants” (24.1 %) and R03B “Other drugs for obstructive airway 
diseases, inhalants” (20.0 %). 
Table 3
Distribution of drugs with frequency of prescriptions in the group “Drugs acting on the respiratory system”
АТС-code Nomenclature Frequency of prescriptions
% from the total number 
of prescriptions
R01A Decongestants and other nasal preparations for topical use 393 25.2
R01B Nasal decongestants for systemic use 3 0.2
R02A Throat preparations 18 1.2
R03A Adrenergics, inhalants 375 24.1
R03B Other drugs for obstructive airway diseases, inhalants 312 20.0
R03D Other systemic drugs for obstructive airway diseases 108 6.9
R05C Expectorants, excluding combinations with cough suppressants 180 11.6
R05D Cough suppressants, excluding combinations with expectorants 3 0.2
R05F Cough suppressants and expectorants, combinations 7 0.4
R05X Other cold preparations 16 1.0
R06A Antihistamines for systemic use 143 9.2
    Total 1558 100
According to the results of the frequency analysis of medical cards of indoor patients in the form of 
trade names of drugs and their international non-proprietary names (INNs), it was established that for their 
appointments doctors used 187 trade names of medicines that contain 73 INNs.
In order to qualitatively evaluate the number of medicinal prescriptions for each trade name, we cal-
culated the intensity of the appointments (Ki) by the formula
i
N
K ,
n
=
 
where N – the number of medical cards indoor patients, where a corresponding drug was available; 
n – the total number of medical records of a indoor patient.
The indicator of the intensity of appointments characterizes the proportion of patients who 
received a specific drug and in the study list of the drug, its value varied in a fairly wide range 
(0.0006 to 0.07). The lowest rates were 70 trademarks of 42 INNs (37.4 %). Such a large number of 
drugs with a low intensity of medical appointments are due to the fact that these drugs were used 
as a pharmacotherapy for concomitant diseases and complications. The highest rates were for only 
2 drugs – Ventolin nebuly and Pulmicort, which were available in 22.3 % and 23.0 % of hospital-
ized patient medical records respectively, that is, every fifth patient.
For a detailed study of the nomenclature of medical prescriptions, the list of trade names 
was analyzed and by manufacturers. It was found that the ratio of drugs of domestic and foreign 
manufacture of drugs is 34.2 % (20 pharmaceutical companies) and 65.8 % (25 producer countries) 
respectively (Fig. 2). 
The largest segment of the volume of foreign production, namely 64 %, is occupied by 
5 countries, such as Great Britain, France, India, Germany and Switzerland. 61 % of the domestic 
production of the nomenclature of drugs represented in the prescriptions is formed by 5 Ukrainian 
pharmaceutical companies, namely «Farmak», «Borshchahivskiy CPP», «Kyivmedpreparat», 
«Pharmaceutical Firm «Darnitsa», «Yuriya-Farm» (Table 4).
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Fig. 2. Cartography of the regions of the world on the level of production of drugs from  
the nomenclature of medical appointments for 2018
Table 4
Leaders of domestic and foreign manufacture of drugs from the nomenclature of medical prescriptions for 
children with asthma
Ukraine Other countries
Pharmaceutical company Number of drugs Country Number of drugs
«Farmak» 15 (8.0 %) Great Britain 18 (9.6 %)
«Borshchahivskiy CPP» 8 (4.3 %) France 18 (9.6 %)
«Kyivmedpreparat» 6 (3.2 %) India 16 (8.6 %)
«Pharmaceutical Firm 
«Darnitsa» 5 (2.7 %) Germany 16 (8.6 %)
«Yuriya -Farm» 5 (2.7 %) Switzerland 11 (5.9 %)
The obtained data indicate a promising direction for domestic pharmaceutical companies 
regarding the development, production and market introduction of drugs used in the treatment of 
asthma in children.
In view of the fact that in children, the use of drugs can cause certain problems, it becomes 
necessary to consider the pharmaceutical design of the drug and the feasibility of its use in the tar-
get age group. The appropriateness and advantage of different dosage forms varies among children, 
especially those with asthma. That is why, at the final stage of our study, the medical forms of trade 
names of drugs were analyzed, which determined the nomenclature of appointments in medical 
cards of inpatient patients. Leading positions in the assortment were pills (25.4 %), sprays (20.4 %) 
and solutions (16.8 %) (Fig. 3). 
Fig. 3. Distribution of drugs nomenclature according to prescriptions for dosage forms
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5. Discussion
The obtained data of the conducted retrospective frequency analysis of the appointments 
of medical devices on archival data of medical cards of inpatient patients allow establishing a 
significant nomenclature of medical appointments for asthma in children. A promising direction 
for domestic pharmaceutical companies in the production of medicines for the treatment of the 
examined nosology was revealed. At the same time, a frequency analysis of the drug nomenclature 
can be used in the selection of medicines for reimbursement and medical insurance programs after 
further pharmacoeconomic studies. 
6. Conclusions
1. Analysis of the data of medical records of inpatient patients showed that the ratio of male 
and female patients, namely 76.5 % and 23.5 %, respectively, does not differ from the data of previ-
ous research on sexual differences in the prevalence of children’s asthma. The average age for boys 
is 11.6 years, and for girls – 10.3.
2. It has been determined that 1983 appointments were made by doctors: the medicinal drugs 
represented by the drug belonging to 11 groups according to the ATC system (A, B, C, D, H, J, N, 
M, P, R, S) – 94.4 %, solutions for washing, irrigation, treatment – 1.5 %, dietary supplements – 
0.3 % and homeopathic preparations – 0.1 %, others – 3.7 %.
3. It was established that for pharmacological therapy of children’s asthma doctors used 187 
trade names of drugs, which contain 73 INNs. By the indicator of the intensity of the appointments, 
70 trade names of the drug substance 42 INNs were determined, accounting for 37.4 % of the total 
number of drug nomenclature. Trade names with the highest rates, which include Ventolin nebuly 
and Pulmicort, were found in the medical card of every fifth inpatient patient.
4. It was investigated that the nomenclature of medical appointments was formed by 26 pro- 
ducing countries, and domestic manufacture of this group of drugs was concentrated in 20 
pharmaceutical companies. The most commonly used dosage forms are tablets (25.4 %), sprays 
(20.4 %) and solutions (16.8 %).
References
[1] Kanavos, P., Schurer, W., Vogler, S. (2011). The Pharmaceutical Distribution Chain in the 
European Union: Structure and Impact on Pharmaceutical Prices. London: London School of Econom-
ics, 120.
[2] Lenney, W., Bush, A., Fitzgerald, D. A., Fletcher, M., Ostrem, A., Pedersen, S. et. al. (2018). 
Improving the global diagnosis and management of asthma in children. Thorax, 73 (7), 662–669. doi: http://
doi.org/10.1136/thoraxjnl-2018-211626 
[3] Ferreira de Magalhães, M., Amaral, R., Pereira, A. M., Sá-Sousa, A., Azevedo, I., Azevedo, L. F., 
Fonseca, J. A. (2017). Cost of asthma in children: A nationwide, population-based, cost-of-illness study. Pe-
diatric Allergy and Immunology, 28 (7), 683–691. doi: http://doi.org/10.1111/pai.12772 
[4] Pro zatverdzhennia ta vprovadzhennia medyko-tekhnolohichnykh dokumentiv zi standartyzat-
sii medychnoi dopomohy pry bronkhialnii astmi (2013). Nakaz MOZ Ukrainy vid 08.10.2013 No. 868. Avail-
able at: https://zakon.rada.gov.ua/rada/show/v0868282-13
[5] Osnovy zakonodavstva Ukrainy pro okhoronu zdorovia (1992). Zakon Ukrainy vid 19.11.1992 
No. 2801-XII. Available at: https://zakon.rada.gov.ua/laws/show/2801-12
[6] Pro zatverdzhennia Kontseptsii rozvytku farmatsevtychnoho sektoru haluzi okhorony zdorovia 
Ukrainy na 2011–2020 roky (2010). Nakaz MOZ Ukrainy vid 13.09.2010. No. 769. Available at: https://zakon.
rada.gov.ua/rada/show/v0769282-10
[7] Piniazhko, O. B. (2016). Analiz realnykh danykh pryznachen likarskykh zasobiv pry poshy-
renykh hinekolohichnykh zakhvoriuvan v Ukraini. Farmatsevtychnyi zhurnal, 3-4, 29–41.
[8] Mishchenko, O. Ya., Yakovlieva, L. V., Ostashko, V. F. (2016). Rezultaty chastotnoho analizu 
pryznachen likarskykh zasobiv khvorym na ishemichnu khvorobu sertsia yak kryterii otsinky yakosti farma-
koterapii. Klinichna farmatsiia, 4, 24–28.
[9] Yakovlieva, L. V., Mishchenko, O. Ya. (2016). Kliniko-ekonomichnyi analiz farmakoterapii kh-
vorykh na liushboishialhiiu. Ratsionalna farmakoterapiia, 2, 19–24.
Original Research Article:
full paper
(2019), «EUREKA: Health Sciences»
Number 3
50
Pharmacology, Toxicology and Pharmaceutical Science
[10] Zaiats, M. M., Zimenkovskyi, A. B. (2013). Kliniko-ekonomichnyi analiz yak skladova opty-
mizatsii farmakoterapii metabolichnoho syndromu. Zaporizkyi medychnyi zhurnal, 4, 10–12.
[11] Masheiko, A. M., Makarenko, O. V., Mavrutenkov, V. V. (2016). Kliniko-ekonomichnyi analiz 
vytrat na farmakoterapiiu hostroho tonzylitu v umovakh statsionaru. Farmatsevtychnyi chasopys, 41, 48–53. 
doi: http://doi.org/10.11603/2312-0967.2016.4.7121 
[12] Tkachova, O. V., Silaiev, A. O. (2016). Kliniko-ekonomichnyi analiz farmakoterapii khvorykh 
na khronichnyi kholetsystyt. Upravlinnia, ekonomika ta zabezpechennia yakosti v farmatsii, 1, 80–85.
[13] Nemchenko, A. S., Balynska, M. V. (2016). Rezultaty kliniko-ekonomichnoho analizu spozhy-
vannia likarskykh preparativ khvorym dytiachoho viku na virusnu diareiu. Upravlinnia, ekonomika ta za-
bezpechennia yakosti v farmatsii, 3, 60–67. 
[14] Tkachova, O. V., Silaiev, A. O. (2016). Kliniko-ekonomichnyi analiz farmakoterapii ditei z hos-
trym nazofarynhitom. Sotsialna farmatsiia v okhoroni zdorovia, 3, 75–82.
[15] Fediak, I. O. (2014). Rezultaty kliniko-ekonomichnoho analizu farmatsevtychnoho zabezpech-
ennia ditei z kashliukom, skarlatynoiu, meninhokokovoiu infektsiieiu. Klinichna farmatsiia, 18 (1), 29–34.
[16] Bieliaieva, O. I. (2012). Kliniko-ekonomichni kharakterystyky farmakoterapii poza likarnianoi 
pnevmonii u ditei. Farmatsevtychnyi chasopys, 4, 163–168.
[17] Gerasymova, O. O., Meshcheryakova, I. V. (2017). Clinical and economic analysis of the 
pharmacotherapy in children with functional dyspepsia. Clinical pharmacy, 21 (1), 19–24. doi: http://doi.
org/10.24959/cphj.17.1415 
[18] Pro zatverdzhennia ta vprovadzhennia medyko-tekhnolohichnykh dokumentiv zi standarty-
zatsii medychnoi dopomohy pry bronkhialnii astmi (2013). Nakaz MOZ Ukrainy vid 08.10.2013. No. 868. 
Available at: https://zakon.rada.gov.ua/rada/show/v0868282-13
[19] Bilak, V. M., Chonka, Ya. V., Bilak, I. D. (2013). Stan reaktyvnosti bronkhiv u ditei, khvo-
rykh na bronkhialnu astmu, pid vplyvom likuvannia metodom speleoterapii. Problemy klinichnoi pediatrii, 
3, 14–17. 
[20] Maidannyk, V. H., Smiian, O. I. (2017). Bronkhialna astma u ditei. Sumy: Sumskyi derzhavnyi 
universytet, 243.
